FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200207186> ?p ?o ?g. }

• W4200207186 endingPage "2441" @default.
• W4200207186 startingPage "2441" @default.
• W4200207186 abstract "Abstract Introduction Black (B) patients with Mycosis fungoides and Sézary Syndrome (MF/SS) have inferior survival and distinct clinical presentations, including many high risk features compared to non-black (NB) patients with MF/SS in large registry studies from the United States. We sought to characterize clinical differences in presentation, treatment, and outcomes to identify drivers of disparities among B patients with MF/SS. Methods We performed a retrospective review of 417 patients with MF/SS diagnosed between 1990 and 2020 at 6 academic institutions in the United States that serve populations with large numbers of Blacks and minorities. Patients with pathologic review and a confirmed histopathologic diagnosis of MF or SS with a stage &gt;1B as their highest TNMB stage were eligible for inclusion. The primary objective was to assess differences in clinical characteristics, treatment patterns, and survival between B and NB patients. Clinical variables included demographics, insurance, zip code, tumor characteristics, and treatment. Descriptive analysis was performed for each variable. Comparison between B and NB patients utilized ANOVA for numerical covariates and chi-square test or Fisher's exact test for categorical covariates. Kaplan-Meier curves for OS were generated, and subgroups were analyzed separated. Results Among 417 patients, 204 (48.9%) were Blacks, 196 (47.0%) were White, and (4.1%) were other races (8 Asian, 5 unknown, 4 Hispanic). The diagnosis was MF in 366 (87.8%), SS in 47 (11.3%), and other 4 patients. Stage at diagnosis was available for 384 patients. 37 (9.6%) were stage 1A, 165 (43%) were stage 1B, 34 (8.9%) were stage 2A, 58 (15.1%) were stage 2B, 44 (11.5%) were stage 3, and 46 (12%) were stage 4 at diagnosis. The median survival of the whole cohort (n=417) was B patients were younger (median 50.1 years in B vs. 60.5 in NB, p&lt;0.001), more often female (49.5% in B; 35.7% in NB, p=0.004), had higher rates of reported lymphadenopathy (78.5% vs. 70%, p=0.039), longer delays from symptom onset to diagnosis (2.0 years in Black vs. 1.2 years in NB, p=0.014), and higher rates of bacteremia at any time in their disease course (19.7% in Black, vs. 6.6% in NB, P&lt; 0.001) compared to NB patients. There was no difference in insurance status (private, Medicare/Medicaid, or uninsured) or comorbidities by race. There was also no differences in overall TNMB stage at diagnosis (p=0.14) compartment stage, or highest stage (p=0.076). Progression to a higher T, N, M, or B stage occurred at similar frequencies in B and NB patients (n=83 (43.2%) in Black and n=73 (38.8%) in NB, p=0.38). Time to first therapy, time to systemic therapy, or total lines of therapy also did not differ by racial group. A greater fraction of B compared to NB patients received systemic therapy but this did not reach statistical significance (72.6% in Black vs. 62% in NB, p=0.060). There was no difference in large cell transformation at any point, or white blood cell count (WBC), lactate dehydrogenase (LDH), or T-cell receptor (TCR) clonality in skin/blood at diagnosis. On univariate analysis, race was not associated with survival; the median survival was 10.5 years (95% CI 8-13.2) in B patients and 10.9 years (95% CI 7.2-14.1) in NB patients. Covariates associated with inferior survival included older age (p&lt;0.001), number of comorbidities (p&lt; 0.001), bacteremia (p&lt; 0.001), higher overall TNMB stage, higher individual T, N, M and B stage, progression to a higher N or M stage, positive TCR in the blood, WBC value, and LDH value. Insurance status and year of diagnosis (prior to 2010, vs. following 2010) were not associated with survival. On multivariate cox proportional hazard model, age at diagnosis, comorbidities, extra-cutaneous disease, bacteremia, TNMB stage at diagnosis, and progression to a higher nodal stage remained statistically significant for survival. Conclusions We present the first multicenter analysis of racial disparities in MF/SS, with nearly 50% B patients. B patients had distinct presentations, delay in diagnosis, and higher rates of bacteremia compared to NB patients. In contrast to US-registry studies, there was no difference in survival between B and NB patients. This finding could be explained by access to academic centers and/or higher rates of insurance coverage among B patients in our cohort. Additional analyses will be updated at the time of the presentation. Figure 1 Figure 1. Disclosures Allen: ADC Therapeutics: Consultancy; Kyowa Kirin: Consultancy; Secure Bio: Consultancy. Mehta: Seattle Genetics; Incyte; TG Therapeutics: Consultancy; Seattle Genetics; Incyte; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Affirmed; Kite/Gilead; Roche-Genetech; Celgene/BMS; Oncotartis; Innate Pharmaceuticals; Seattle Genetics; Incyte; Takeda; Fortyseven Inc/Gilead; TG Therapeutics; Merck; Juno Pharmaceuticals/Bristol Myers Squibb: Research Funding. Huen: Rhizen: Research Funding; Elorac: Research Funding; Kyowa Kirin: Research Funding; Tillium: Research Funding; Innate: Research Funding; Galderma: Research Funding; Miragen: Research Funding. Porcu: Viracta: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Innate Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; Daiichi: Honoraria, Research Funding; Kiowa: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Spectrum: Consultancy; DrenBio: Consultancy." @default.
• W4200207186 created "2021-12-31" @default.
• W4200207186 creator A5012121701 @default.
• W4200207186 creator A5016681747 @default.
• W4200207186 creator A5017284444 @default.
• W4200207186 creator A5027071793 @default.
• W4200207186 creator A5027978665 @default.
• W4200207186 creator A5030631799 @default.
• W4200207186 creator A5034233224 @default.
• W4200207186 creator A5041744225 @default.
• W4200207186 creator A5041950455 @default.
• W4200207186 creator A5043541884 @default.
• W4200207186 creator A5056186554 @default.
• W4200207186 creator A5061066145 @default.
• W4200207186 creator A5064395419 @default.
• W4200207186 creator A5073847352 @default.
• W4200207186 creator A5083914569 @default.
• W4200207186 creator A5088684047 @default.
• W4200207186 creator A5090753236 @default.
• W4200207186 date "2021-11-05" @default.
• W4200207186 modified "2023-09-30" @default.
• W4200207186 title "No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis" @default.
• W4200207186 doi "https://doi.org/10.1182/blood-2021-151911" @default.
• W4200207186 hasPublicationYear "2021" @default.
• W4200207186 type Work @default.
• W4200207186 citedByCount "0" @default.
• W4200207186 crossrefType "journal-article" @default.
• W4200207186 hasAuthorship W4200207186A5012121701 @default.
• W4200207186 hasAuthorship W4200207186A5016681747 @default.
• W4200207186 hasAuthorship W4200207186A5017284444 @default.
• W4200207186 hasAuthorship W4200207186A5027071793 @default.
• W4200207186 hasAuthorship W4200207186A5027978665 @default.
• W4200207186 hasAuthorship W4200207186A5030631799 @default.
• W4200207186 hasAuthorship W4200207186A5034233224 @default.
• W4200207186 hasAuthorship W4200207186A5041744225 @default.
• W4200207186 hasAuthorship W4200207186A5041950455 @default.
• W4200207186 hasAuthorship W4200207186A5043541884 @default.
• W4200207186 hasAuthorship W4200207186A5056186554 @default.
• W4200207186 hasAuthorship W4200207186A5061066145 @default.
• W4200207186 hasAuthorship W4200207186A5064395419 @default.
• W4200207186 hasAuthorship W4200207186A5073847352 @default.
• W4200207186 hasAuthorship W4200207186A5083914569 @default.
• W4200207186 hasAuthorship W4200207186A5088684047 @default.
• W4200207186 hasAuthorship W4200207186A5090753236 @default.
• W4200207186 hasBestOaLocation W42002071861 @default.
• W4200207186 hasConcept C10515644 @default.
• W4200207186 hasConcept C126322002 @default.
• W4200207186 hasConcept C146357865 @default.
• W4200207186 hasConcept C151730666 @default.
• W4200207186 hasConcept C16005928 @default.
• W4200207186 hasConcept C167135981 @default.
• W4200207186 hasConcept C191093355 @default.
• W4200207186 hasConcept C2777756187 @default.
• W4200207186 hasConcept C2779338263 @default.
• W4200207186 hasConcept C71924100 @default.
• W4200207186 hasConcept C86803240 @default.
• W4200207186 hasConceptScore W4200207186C10515644 @default.
• W4200207186 hasConceptScore W4200207186C126322002 @default.
• W4200207186 hasConceptScore W4200207186C146357865 @default.
• W4200207186 hasConceptScore W4200207186C151730666 @default.
• W4200207186 hasConceptScore W4200207186C16005928 @default.
• W4200207186 hasConceptScore W4200207186C167135981 @default.
• W4200207186 hasConceptScore W4200207186C191093355 @default.
• W4200207186 hasConceptScore W4200207186C2777756187 @default.
• W4200207186 hasConceptScore W4200207186C2779338263 @default.
• W4200207186 hasConceptScore W4200207186C71924100 @default.
• W4200207186 hasConceptScore W4200207186C86803240 @default.
• W4200207186 hasIssue "Supplement 1" @default.
• W4200207186 hasLocation W42002071861 @default.
• W4200207186 hasOpenAccess W4200207186 @default.
• W4200207186 hasPrimaryLocation W42002071861 @default.
• W4200207186 hasRelatedWork W1989738791 @default.
• W4200207186 hasRelatedWork W2169002005 @default.
• W4200207186 hasRelatedWork W2352414543 @default.
• W4200207186 hasRelatedWork W2385182208 @default.
• W4200207186 hasRelatedWork W2406872459 @default.
• W4200207186 hasRelatedWork W3130723548 @default.
• W4200207186 hasRelatedWork W3211903024 @default.
• W4200207186 hasRelatedWork W4224870306 @default.
• W4200207186 hasRelatedWork W4294543563 @default.
• W4200207186 hasRelatedWork W4312049285 @default.
• W4200207186 hasVolume "138" @default.
• W4200207186 isParatext "false" @default.
• W4200207186 isRetracted "false" @default.
• W4200207186 workType "article" @default.